FDA — authorised 27 June 1960
- Marketing authorisation holder: PAR STERILE PRODUCTS
- Status: approved
🇺🇸 Brevital Sodium in United States
FDA authorised Brevital Sodium on 27 June 1960
Marketing authorisations
FDA — authorised 27 June 1960
- Application: NDA011559
- Marketing authorisation holder: PH HEALTH
- Local brand name: BREVITAL SODIUM
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 3 October 2024
- Application: ANDA215488
- Marketing authorisation holder: ONESOURCE SPECIALTY
- Status: approved
Brevital Sodium in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Metabolic approved in United States
Frequently asked questions
Is Brevital Sodium approved in United States?
Yes. FDA authorised it on 27 June 1960; FDA authorised it on 27 June 1960; FDA authorised it on 3 October 2024.
Who is the marketing authorisation holder for Brevital Sodium in United States?
PAR STERILE PRODUCTS holds the US marketing authorisation.